Alliance Global Partners lowered the firm’s price target on PDS Biotechnology (PDSB) to $4.50 from $7 and keeps a Buy rating on the ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial design Efti in ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...